The first clinical application of universal CAR-T cells was reported by Qasim et al. (2015) at ASH 2015; a 1-year-old girl with relapsed leukemia achieved molecular remission without significant toxicity after transcription activator-like effector nucleases (Talen) engineered anti-CD19 UCAR-T cell infusion following lymphodepleting conditioning with Flu 90 mg/m2, Cy 1.5 g/m2, and alemtuzumab 1 mg/kg, providing early proof-of-concept evidence for this strategy. Here, CD19 is linked to leukemia.